Robert Vonderheide, MD, DPhil
Abramson Cancer Center at Penn Medicine
3
3
3
N/A
0
5
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (3)
Research Network
Collaboration Network
Research Areas & Affiliations
Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
Lizhi Niu, PhD
Fuda Cancer Hospital
Shared therapeutic areas:
Ciro Gallo, M.D., Ph.D.
University of Campania Luigi Vanvitelli
Shared therapeutic areas:
Zhaoping Li, MD, PhD
University of California, Los Angeles
Shared therapeutic areas:
Dong-Xin Wang, MD, PhD
Peking University First Hospital
Shared therapeutic areas:
Jeong Min Lee, MD
Seoul National University Hospital
Shared therapeutic areas:
Hagop Youssoufian, MD
Verastem, Inc.
Shared therapeutic areas:
Gustavo Leone
Medical University of South Carolina, Hollings Cancer Center
Shared therapeutic areas:
Steven A Rosenberg, M.D.
National Cancer Institute (NCI)
Shared therapeutic areas:
Stanislaw R. Burzynski, MD, PhD
Burzynski Research Institute
Shared therapeutic areas:
Deborah E Citrin, M.D.
National Cancer Institute (NCI)
Shared therapeutic areas:
Publications (0)
No publications found for this investigator.
Clinical Trials (3)
Showing 3 of 3 trials
Study of Neo-adjuvant RO7009789 Alone or Neo-adjuvant RO7009789 Plus Nab-Paclitaxel and Gemcitabine Followed by Adjuvant RO7009789 Plus Nab-Paclitaxel and Gemcitabine for Patients With Newly Diagnosed Resectable Pancreatic Carcinoma
Tremelimumab and CP-870,893 in Patients With Metastatic Melanoma
Phase 1 Study of Preoperative Gemcitabine Plus CP-870, 893 Followed by Addition of CP-870,893 to Standard -Of-care Adjuvant Chemoradiation for Patients With Newly Diagnosed Resectable Pancreatic Carcinoma
All 3 trials loaded